The United Kingdom is witnessing a noticeable surge in interest surrounding copyright substances. Beyond the well-established use of psilocybin and LSD, scientists and enthusiasts are increasingly exploring less-charted areas, particularly copyright and the budding cannabinoid, CBG. This burgeoning scene encompasses clinical trials into psychologic